K-MEDI Hub Advances Joint Research for Autoimmune Disease Treatment Development

6 Years, 24.8 Billion KRW Invested to Support Domestic New Drug Development

[Asia Economy Yeongnam Reporting Headquarters Reporter Koo Dae-sun] K-Medi Hub (Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation, Chairman Yang Jin-young) has decided to jointly research autoimmune disease treatment pipelines with domestic companies.

Ajos Bio Co., Ltd. has been selected as the recipient of K-Medi Hub's 2023 Synthetic New Drug Industry-Academia Collaboration Support Project, and both parties will conduct joint research going forward.

This project, running from 2022 to 2027, involves a total budget of 24.8 billion KRW to support the optimization of early-stage pipelines and commercialization of domestic new drug development institutions.

The project plans to support the pipeline optimization technical capabilities of K-Medi Hub to the proposing institutions and provide maximum support for any technology gaps.

Ajos Bio Co., Ltd. (CEO Shin Jae-min) is a bio company focused on new drug discovery and drug delivery system development based on an artificial intelligence platform.

Currently, it is independently developing anticancer drug candidates and drug delivery systems, and conducting joint research with various pharmaceutical and bio companies.

K-Medi Hub and Ajos Bio Co., Ltd. plan to jointly develop innovative mechanism autoimmune disease treatments based on their excellent R&D capabilities.

Chairman Yang Jin-young said, “Autoimmune diseases are caused by various factors and affect all organs and systems of the body, making it a field where treatment development is actively pursued both domestically and internationally. Through this project, we will provide maximum support with K-Medi Hub’s professional personnel and infrastructure to enable the development of treatments for autoimmune diseases.”

K-MEDI Hub New Drug Development Support Center.

This content was produced with the assistance of AI translation services.